Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$19.95 USD
-0.05 (-0.25%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $19.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.95 USD
-0.05 (-0.25%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $19.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Zacks News
Why Is Catalyst (CPRX) Up 4.4% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst's (CPRX) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2020.
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and -6.10%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Catalyst (CPRX) will provide updates on earnings and revenues when its releases third-quarter 2020 results.
Why Is Catalyst (CPRX) Down 7.5% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst (CPRX) Eyes Firdapse Label Expansion Amid Competition
by Zacks Equity Research
Catalyst's (CPRX) efforts to expand Firdapse label are encouraging. However, with only a few candidates in the pipeline, the company's dependence on Firdapse for growth remains a matter of concern.
Catalyst's (CPRX) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Catalyst (CPRX) beats both earnings and sales estimates in the second quarter of 2020.
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 12.50% and 2.20%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Catalyst Pharmaceutical (CPRX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst (CPRX) Down 0.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Catalyst (CPRX) beats on Q1 earnings but misses on revenues. It also withdraws sales guidance due to the coronavirus pandemic.
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 11.11% and -8.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Catalyst (CPRX) Up 52.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst's (CPRX) Q4 Earnings Miss Estimates, Revenues Meet
by Zacks Equity Research
Catalyst's (CPRX) earnings lag estimates in the fourth quarter. Revenues match the same.
Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Catalyst (CPRX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Catalyst (CPRX) stock based on the movements in the options market lately.
Implied Volatility Surging for Catalyst (CPRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Catalyst (CPRX) stock based on the movements in the options market lately.
Catalyst Gives Preliminary Firdapse Estimates & Other Updates
by Zacks Equity Research
Catalyst (CPRX) provides preliminary estimates for Firdapse and other corporate updates for 2019.
Why Is Catalyst (CPRX) Down 5.3% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst Focuses on Firdapse Label Expansion Amid Competition
by Zacks Equity Research
Catalyst (CPRX) focuses on the development of Firdapse for additional indications.
Catalyst's (CPRX) Q3 Earnings Beat Estimates, Sales Miss
by Zacks Equity Research
Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2019.
Catalyst Pharmaceutical (CPRX) Beats Q3 Earnings Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 18.18% and -8.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharma (CPRX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
During Catalyst's (CPRX) third-quarter 2019 conference call, investor focus will be on the sales performance of its only marketed drug Firdapse and its label expansion studies.
Investors Can Find Strong Stocks with our First Profit Screen
by Benjamin Rains
Today, we are utilizing our 'First Profit' stock screen to help investors find strong stocks. The idea is to search for companies that just reported their first quarterly profit within the last year...
Learn How to Find Top-Ranked 'Cheap' Stocks Under $10 with this Screener
by Benjamin Rains
Searching for 'cheap' stocks that look poised to climb can be an attractive investment strategy. But investors have to know where and how to find strong stocks trading under $10 a share. So check out this Zacks Stock Screener...